Author

Silvia Basilico

Observed institution: Autolus (United Kingdom)

OpenAlex ID: A5045405392

Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma

2023 · Claire Roddie, Lazaros J. Lekakis, et al. · Blood · 74

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial

2024 · Kate Cwynarski, Gloria Iacoboni, et al. · Nature Medicine · 47

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

2022 · Kate Cwynarski, Gloria Iacoboni, et al. · Blood · 28

P157 Obecabtagene autoleucel, a CD19-targeting autologous chimeric antigen receptor T-cell therapy, in patients with severe, refractory systemic lupus erythematosus: Phase I CARLYSLE preliminary results

2026 · Maria Leandro, Ruth Pepper, et al. · Lara D. Veeken

LBS1:02 CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel (obe-cel), in severe refractory systemic lupus erythematosus (srSLE): initial results from phase I CARLYSLE study

2026 · Maria Leandro, Ruth Pepper, et al.

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

2025 · Claire Roddie, Maria Leandro, et al. · Blood

S262: Safety and Efficacy of Obecabtagene Autoleucel (obe-cel), a Fast-off Rate Cd19 Car in Relapsed/refractory Adult B-cell Acute Lymphoblastic Leukaemia:top Line Results of the Pivotal Felix Study

2023 · Claire Roddie, Karamjeet Sandhu, et al. · HemaSphere

Works count: 7

Citation count: 147

H-index: 3

I10-index: 3